Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance.

BACKGROUND: Preventing the emergence of anti-malarial drug resistance is critical for the success of current malaria elimination efforts. Prevention strategies have focused predominantly on qualitative factors, such as choice of drugs, use of combinations and deployment of multiple first-line treat...

Full description

Bibliographic Details
Main Authors: White, N, Pongtavornpinyo, W, Maude, R, Saralamba, S, Aguas, R, Stepniewska, K, Lee, S, Dondorp, A, White, L, Day, N
Format: Journal article
Language:English
Published: BioMed Central 2009
_version_ 1826263096833867776
author White, N
Pongtavornpinyo, W
Maude, R
Saralamba, S
Aguas, R
Stepniewska, K
Lee, S
Dondorp, A
White, L
Day, N
author_facet White, N
Pongtavornpinyo, W
Maude, R
Saralamba, S
Aguas, R
Stepniewska, K
Lee, S
Dondorp, A
White, L
Day, N
author_sort White, N
collection OXFORD
description BACKGROUND: Preventing the emergence of anti-malarial drug resistance is critical for the success of current malaria elimination efforts. Prevention strategies have focused predominantly on qualitative factors, such as choice of drugs, use of combinations and deployment of multiple first-line treatments. The importance of anti-malarial treatment dosing has been underappreciated. Treatment recommendations are often for the lowest doses that produce "satisfactory" results. METHODS: The probability of de-novo resistant malaria parasites surviving and transmitting depends on the relationship between their degree of resistance and the blood concentration profiles of the anti-malarial drug to which they are exposed. The conditions required for the in-vivo selection of de-novo emergent resistant malaria parasites were examined and relative probabilities assessed. RESULTS: Recrudescence is essential for the transmission of de-novo resistance. For rapidly eliminated anti-malarials high-grade resistance can arise from a single drug exposure, but low-grade resistance can arise only from repeated inadequate treatments. Resistance to artemisinins is, therefore, unlikely to emerge with single drug exposures. Hyperparasitaemic patients are an important source of de-novo anti-malarial drug resistance. Their parasite populations are larger, their control of the infection insufficient, and their rates of recrudescence following anti-malarial treatment are high. As use of substandard drugs, poor adherence, unusual pharmacokinetics, and inadequate immune responses are host characteristics, likely to pertain to each recurrence of infection, a small subgroup of patients provides the particular circumstances conducive to de-novo resistance selection and transmission. CONCLUSION: Current dosing recommendations provide a resistance selection opportunity in those patients with low drug levels and high parasite burdens (often children or pregnant women). Patients with hyperparasitaemia who receive outpatient treatments provide the greatest risk of selecting de-novo resistant parasites. This emphasizes the importance of ensuring that only quality-assured anti-malarial combinations are used, that treatment doses are optimized on the basis of pharmacodynamic and pharmacokinetic assessments in the target populations, and that patients with heavy parasite burdens are identified and receive sufficient treatment to prevent recrudescence.
first_indexed 2024-03-06T19:46:17Z
format Journal article
id oxford-uuid:2268eb69-3590-42ec-a302-60a8a4c87e61
institution University of Oxford
language English
last_indexed 2024-03-06T19:46:17Z
publishDate 2009
publisher BioMed Central
record_format dspace
spelling oxford-uuid:2268eb69-3590-42ec-a302-60a8a4c87e612022-03-26T11:38:39ZHyperparasitaemia and low dosing are an important source of anti-malarial drug resistance.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2268eb69-3590-42ec-a302-60a8a4c87e61EnglishSymplectic Elements at OxfordBioMed Central2009White, NPongtavornpinyo, WMaude, RSaralamba, SAguas, RStepniewska, KLee, SDondorp, AWhite, LDay, N BACKGROUND: Preventing the emergence of anti-malarial drug resistance is critical for the success of current malaria elimination efforts. Prevention strategies have focused predominantly on qualitative factors, such as choice of drugs, use of combinations and deployment of multiple first-line treatments. The importance of anti-malarial treatment dosing has been underappreciated. Treatment recommendations are often for the lowest doses that produce "satisfactory" results. METHODS: The probability of de-novo resistant malaria parasites surviving and transmitting depends on the relationship between their degree of resistance and the blood concentration profiles of the anti-malarial drug to which they are exposed. The conditions required for the in-vivo selection of de-novo emergent resistant malaria parasites were examined and relative probabilities assessed. RESULTS: Recrudescence is essential for the transmission of de-novo resistance. For rapidly eliminated anti-malarials high-grade resistance can arise from a single drug exposure, but low-grade resistance can arise only from repeated inadequate treatments. Resistance to artemisinins is, therefore, unlikely to emerge with single drug exposures. Hyperparasitaemic patients are an important source of de-novo anti-malarial drug resistance. Their parasite populations are larger, their control of the infection insufficient, and their rates of recrudescence following anti-malarial treatment are high. As use of substandard drugs, poor adherence, unusual pharmacokinetics, and inadequate immune responses are host characteristics, likely to pertain to each recurrence of infection, a small subgroup of patients provides the particular circumstances conducive to de-novo resistance selection and transmission. CONCLUSION: Current dosing recommendations provide a resistance selection opportunity in those patients with low drug levels and high parasite burdens (often children or pregnant women). Patients with hyperparasitaemia who receive outpatient treatments provide the greatest risk of selecting de-novo resistant parasites. This emphasizes the importance of ensuring that only quality-assured anti-malarial combinations are used, that treatment doses are optimized on the basis of pharmacodynamic and pharmacokinetic assessments in the target populations, and that patients with heavy parasite burdens are identified and receive sufficient treatment to prevent recrudescence.
spellingShingle White, N
Pongtavornpinyo, W
Maude, R
Saralamba, S
Aguas, R
Stepniewska, K
Lee, S
Dondorp, A
White, L
Day, N
Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance.
title Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance.
title_full Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance.
title_fullStr Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance.
title_full_unstemmed Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance.
title_short Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance.
title_sort hyperparasitaemia and low dosing are an important source of anti malarial drug resistance
work_keys_str_mv AT whiten hyperparasitaemiaandlowdosingareanimportantsourceofantimalarialdrugresistance
AT pongtavornpinyow hyperparasitaemiaandlowdosingareanimportantsourceofantimalarialdrugresistance
AT mauder hyperparasitaemiaandlowdosingareanimportantsourceofantimalarialdrugresistance
AT saralambas hyperparasitaemiaandlowdosingareanimportantsourceofantimalarialdrugresistance
AT aguasr hyperparasitaemiaandlowdosingareanimportantsourceofantimalarialdrugresistance
AT stepniewskak hyperparasitaemiaandlowdosingareanimportantsourceofantimalarialdrugresistance
AT lees hyperparasitaemiaandlowdosingareanimportantsourceofantimalarialdrugresistance
AT dondorpa hyperparasitaemiaandlowdosingareanimportantsourceofantimalarialdrugresistance
AT whitel hyperparasitaemiaandlowdosingareanimportantsourceofantimalarialdrugresistance
AT dayn hyperparasitaemiaandlowdosingareanimportantsourceofantimalarialdrugresistance